[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Orlando Health, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":196},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,71,93,120,148,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100638365","randomized-trial-of-next-generation-fluoroscopy-system-vs-conventional-fluoroscopy-system-in-endoscopy-100638365",false,"NCT07594132","Randomized Trial of Next Generation Fluoroscopy System vs. Conventional Fluoroscopy System in Endoscopy","Randomized Trial Comparing Next Generation Fluoroscopy System With Conventional Fluoroscopy System in Fluoroscopy-guided Endoscopic Procedures","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients undergoing fluoroscopy-guided endoscopic procedure\n* Physicians and anesthesia staff participating in endoscopic procedures\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy","ALL","18 Years",{"count":19,"type":20},108,"ESTIMATED","INTERVENTIONAL",[23],"NA","Fluoroscopy is an integral part of both basic and advanced gastrointestinal endoscopy procedures. Given the risks of radiation exposure and inherent limitations of preventive measures, there is a need for additional effective protective methods.\n\nIn this randomized trial, we will be comparing radiation exposure between a next generation fluoroscopy system and conventional fluoroscopy system during fluoroscopy-guided endoscopic procedures.",[26],"Radiation Exposure",[28,29,30,31],"Endoscopic ultrasound","Endoscopic retrograde cholangiopancreatography","Endoscopy","Fluoroscopy","RECRUITING","2026-05-11",{"date":35,"type":36},"2026-05-18","ACTUAL",{"date":38,"type":20},"2026-05",{"date":40,"type":20},"2028-04",{"name":42,"class":43},"Orlando Health, Inc.","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100624212","strategic-timing-of-endoscopic-interventions-in-infected-necrotizing-pancreatitis-100624212","NCT07406698","Strategic Timing of Endoscopic Interventions in Infected Necrotizing Pancreatitis","Strategic Timing of Endoscopic Procedural Interventions in Infected Necrotizing Pancreatitis: The STEP-IN Trial","STEP-IN","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients with symptomatic necrotic collection diagnosed on MRI or CT abdomen\u002Fpelvis, defined as fluid collection in the setting of documented pancreatic necrosis that contains necrotic material and encased within a partial or complete wall.\n3. Documented or suspected infected necrotizing pancreatitis 1) Documented infected necrotizing pancreatitis, defined as: i. Positive culture obtained with percutaneous fine needle aspiration from the pancreatic necrotic collection (if intervention is undertaken ≤14 days of onset of acute pancreatitis) ii. OR gas in the necrotic collection on imaging at any time. 2) Suspected infected necrotizing pancreatitis, if \\>14 days after onset of disease, defined as: i. Persistent organ failure in patients admitted to the ICU ii. OR presence of at least three of the following six clinical\u002Flaboratory parameters (SIRS criteria or elevated CRP or elevated procalcitonin) with no other infection focus. These clinical criteria are considered sufficiently reliable only after the initial 14 days of acute pancreatitis:\n\n   1. Temperature \\>100.4 °F or \\\u003C96.8 °F\n   2. Heart rate \\> 90 beats\u002Fmin\n   3. Respiratory rate \\>20 breaths\u002Fmin or PaCO2 \\\u003C 32 mmHg\n   4. WBC count \\>12,000\u002Fmm³, or \\\u003C4,000\u002Fmm³, or more than 10% immature band cells\n   5. CRP ≥ 30mg\u002FL\n   6. Procalcitonin ≥ 1ng\u002FmL\n4. Endoscopic drainage of the necrotic collection is technically feasible as deemed by the treating physician.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. \\> 26 days after the onset of acute pancreatitis\n3. Indication for emergency laparotomy for abdominal catastrophe (e.g. bleeding, bowel perforation, abdominal compartment syndrome).\n4. Necrotic collection is not amenable for endoscopic intervention.\n5. Pregnancy.\n6. Unable to obtain informed consent from the patient or legally authorized representative.",{"count":54,"type":20},104,[23],"Pancreatic necrosis complicates approximately 20-30% of severe acute pancreatitis cases. While many collections resolve without intervention, persistent symptomatic collections-particularly when infected-are associated with significant morbidity and mortality and frequently require procedural management. Current guidelines recommend delaying intervention until collections are fully walled off, typically around four weeks. However, in clinical practice, many patients deteriorate before this window is reached.\n\nProspective data from our institution, supported by recent meta-analyses, suggest that early intervention using modern endoscopic techniques can be performed safely, even when undertaken within the first four weeks of disease onset. We believe that, in appropriately selected patients, early endoscopic intervention may prevent clinical deterioration, reduce complications, shorten hospital stay, and decrease overall healthcare utilization compared with a delayed approach.\n\nTo formally evaluate this strategy, an international, multicenter randomized trial is being conducted, entitled Strategic Timing of Endoscopic Procedural Interventions in Infected Necrotizing Pancreatitis (STEP-IN Trial).",[58],"Pancreatitis, Acute Necrotizing",[28,60,61,62],"Drainage","Necrotic collection","Timing of intervention","2026-02-09",{"date":65,"type":36},"2026-02-12",{"date":67,"type":20},"2026-01-28",{"date":69,"type":20},"2029-12-31",{"name":42,"class":43},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100529875","registry-of-patients-undergoing-endoscopic-management-of-pancreatic-fluid-collections-100529875","NCT06179459","Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections","Inclusion Criteria:\n\n* Age ≥ 18 years\n* All patients undergoing endoscopic treatment of pancreatic fluid collections\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients who did not receive endoscopic treatment of pancreatic fluid collections",{"count":78,"type":20},1000,"OBSERVATIONAL","Acute pancreatitis is one of the most common gastrointestinal disorders requiring hospitalization worldwide. Pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis.\n\nSymptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. The aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.",[82,83,84],"Acute Pancreatitis","Pancreatic Pseudocyst","Pancreatic Necrosis","2025-11-03",{"date":87,"type":36},"2025-11-04",{"date":89,"type":36},"2021-05-01",{"date":91,"type":20},"2032-12",{"name":42,"class":43},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100559472","artificial-intelligence-in-endoscopic-ultrasound-100559472","NCT06564571","Artificial Intelligence in Endoscopic Ultrasound","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any patient undergoing endoscopic ultrasound examination\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years","100 Years",{"count":101,"type":20},310,"The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.",[104,105,106],"Pancreatic Cancer","Pancreas Disease","Pancreatic Cyst",[108,109,110,111],"pancreatic disease","pancreatic cancer","pancreatic cyst","artificial intelligence","2025-05-27",{"date":114,"type":36},"2025-05-31",{"date":116,"type":36},"2024-01-19",{"date":118,"type":20},"2027-12",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":139,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":147,"locationsCount":44},"100542265","eus-examination-using-endosound-vision-system-vs-standard-echoendoscope-100542265","NCT06340620","EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope","Randomized Trial of Endoscopic Ultrasound Examination Using EndoSound Vision System vs. Standard Echoendoscope","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Any patient undergoing EUS examination for evaluation of the pancreas, bile duct, mediastinal or intraabdominal lymph nodes, or luminal lesions in the esophagus, stomach, duodenum or colon.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Unable to obtain consent for the procedure from either the patient or LAR.\n* Intrauterine pregnancy.",{"count":128,"type":20},140,[23],"This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.",[132,104,106,133,134,135,136,137,138],"Pancreatic Disease","Gastrointestinal Tumor","Bile Duct Diseases","Bile Duct Cancer","Lymph Node Disease","Submucosal Tumor of Gastrointestinal Tract","Gastrointestinal Cancer",[28,140,141],"EndoSound Vision System","Randomized trial","2024-03-25",{"date":144,"type":36},"2024-04-01",{"date":142,"type":20},{"date":118,"type":20},{"name":42,"class":43},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":44},"100529787","eus-guided-celiac-plexus-block-vs-sham-in-chronic-pancreatitis-100529787","NCT06178315","EUS-guided Celiac Plexus Block vs. Sham in Chronic Pancreatitis","Randomized Trial of EUS-guided Celiac Plexus Block vs. Sham for Palliation of Pain in Chronic Pancreatitis","EPOCH","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Abdominal pain of at least 3 months duration and a VAS score ≥ 3, with or without the use of narcotic analgesics.\n* Diagnosis of chronic pancreatitis on EUS examination, with ≥ 5 features on EUS.\n* No other cause of abdominal pain\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* History of prior EUS-CPB.\n* Use of anticoagulants that cannot be discontinued for the procedure.\n* Clinically significant allergy to bupivacaine or triamcinolone.\n* Unable to obtain consent for the procedure from either the patient or LAR.\n* Intrauterine pregnancy.",{"count":157,"type":20},94,[23],"The aim of this randomized trial is to assess the efficacy of EUS-CPB in the alleviation of abdominal pain in patients with chronic pancreatitis.",[161],"Chronic Pancreatitis","2023-12-18",{"date":164,"type":36},"2023-12-21",{"date":166,"type":36},"2023-12-07",{"date":168,"type":20},"2026-12-31",{"name":42,"class":43},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":44},"100481308","evaluation-of-3d-printed-myoelectric-prosthetic-devices-in-children-with-upper-congenital-limb-deficiency-100481308","NCT05547308","Evaluation of 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency","Evaluation of Gamified Training for 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency","Inclusion Criteria:\n\n* Children between the ages of 7 to 17\n* Congenital\u002Finfant upper limb deficiency specifically transhumeral and transradial limb deficiency as identified by Limbitless Solutions.\n\nExclusion Criteria:\n\n* Non-English-speaking children and families.\n* Any shoulder or wrist disarticulation will be excluded.","7 Years","17 Years",{"count":180,"type":20},20,[23],"This will be a prospective study over a 14-month duration with clinical evaluations throughout. Limitless Solutions will provide prosthetics and training system for study subjects that qualify for enrollment.",[184,185,186],"Limb Deformities, Congenital","Upper Extremity Deformities, Congenital","Congenital Abnormalities","NOT_YET_RECRUITING","2022-09-16",{"date":190,"type":36},"2022-09-21",{"date":192,"type":20},"2022-11",{"date":194,"type":20},"2027-11",{"name":42,"class":43},""]